Thyroid Cancer Management
Introduction
- The American College of Surgeons recommends total or near-total thyroidectomy as the standard of care for stage 3 follicular thyroid cancer, with long-term survival rates exceeding 90% when managed with total thyroidectomy followed by radioactive iodine ablation and TSH suppression therapy 1
Surgical Management
- Total or near-total thyroidectomy is the standard of care for stage 3 follicular thyroid cancer, and should be performed by an experienced surgeon to minimize complications such as laryngeal nerve palsy and hypoparathyroidism (which occur in <1-2% of cases) 1
- Compartment-oriented lymph node dissection should be performed if lymph node metastases are suspected or confirmed 1
Post-Surgical Radioactive Iodine (RAI) Ablation
- RAI ablation (30-100 mCi) is strongly recommended for stage 3 disease to eliminate any residual thyroid tissue and microscopic tumor foci 1
- Preparation for RAI should be done with recombinant human TSH (rhTSH) while the patient remains on levothyroxine therapy 1, 2
Prognosis and Monitoring
- Patients >45 years have worse prognosis 1
- Complete remission can be achieved in two-thirds of patients with local disease 1
- Distant metastases (most commonly to lungs and bones) significantly worsen prognosis 1
- Bone metastases have the worst prognosis even with aggressive treatment 1
- Regular follow-up is essential as recurrences can occur many years after initial treatment 2
The following table defines response to therapy based on Tg and imaging results:
Response Tg Imaging Excellent Undetectable Negative Biochemical incomplete Detectable Negative Structural incomplete Detectable Positive Indeterminate Detectable Indeterminate
Treatment of Recurrence
- Patients with persistent disease or increasing Tg levels require imaging for localization and appropriate treatment 1
- Treatment of locoregional recurrence combines surgery and radioiodine therapy 1
- External beam radiotherapy may be indicated when complete surgical excision is not possible or when there is no significant radioiodine uptake 1
- Lenvatinib and sorafenib are FDA-approved for locally recurrent or metastatic, progressive, radioactive iodine-refractory disease, demonstrating significant PFS improvement and objective response rate, as recommended by the National Comprehensive Cancer Network 3
Follow-up and Surveillance
- Initial assessment (6-8 weeks post-treatment) should include TSH, free T4, Tg, and TgAb measurements to adjust levothyroxine dose, as recommended by the American Association of Clinical Endocrinologists 3
- Long-term monitoring should be based on response to treatment, with the following frequency:
TSH targets should be based on risk stratification and response to treatment, with the following targets:
Risk Stratification Target TSH Level High-risk <0.1 μIU/mL Intermediate-risk 0.1-0.5 μIU/mL Low-risk 0.5-2.0 μIU/mL, as recommended by the American Thyroid Association [3] Annual follow-up with thyroid function tests and ultrasound is recommended for asymptomatic patients with normal TSH, and more intensive surveillance is required for post-treatment malignancy based on risk stratification, as recommended by the American Society of Clinical Oncology 4, 3
Risk Stratification and Treatment Recommendations
- Risk stratification should consider histological type, size, extrathyroidal extension, and distant metastases, with specific risk categories including low-risk, intermediate-risk, and high-risk, as defined by the American Thyroid Association and the National Comprehensive Cancer Network 3, 5
- Treatment recommendations vary based on risk stratification, with total or near-total thyroidectomy recommended for tumors >1 cm, multifocal disease, bilateral disease, extrathyroidal extension, familial disease, lymph node involvement, and distant metastases, according to the National Comprehensive Cancer Network 6
- Observation without RAI may be considered if postoperative Tg is <1 ng/mL, with TSH target 0.5-2.0 μIU/mL, and surveillance every 12-24 months, as recommended by the National Comprehensive Cancer Network 7, 3